Clinical Trials Browser

Phase 2 × Ustekinumab × 90 days × Clear all

NCT06807593 2026-03-05

Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients

Phase 2 Recruiting

Neoplasms

NCT04572815 2026-01-02

Ustekinumab for the Prevention of Acute Graft-versus-Host Disease After Unrelated Donor Hematopoietic Cell Transplant

Phase 2 Active not recruiting

Hematologic Diseases